Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Non-Current Assets: 2023-2024

Historic Non-Current Assets for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $11.8 million.

  • BioLineRx's Non-Current Assets fell 26.35% to $11.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.4 million, marking a year-over-year decrease of 26.35%. This contributed to the annual value of $11.8 million for FY2024, which is 29.51% down from last year.
  • According to the latest figures from FY2024, BioLineRx's Non-Current Assets is $11.8 million, which was down 29.51% from $16.7 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Non-Current Assets ranged from a high of $16.7 million in FY2023 and a low of $11.8 million during FY2024.
  • Its 2-year average for Non-Current Assets is $14.3 million, with a median of $14.3 million in 2023.
  • Data for BioLineRx's Non-Current Assets shows a maximum YoY declined of 29.51% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Non-Current Assets (Yearly) stood at $16.7 million in 2023, then fell by 29.51% to $11.8 million in 2024.